Abstract
MCL-063 Multicohort Study of Conditional Survival and Cause of Death After Achieving Event-Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL)
Clinical lymphoma, myeloma and leukemia, Vol.23(Suppl. 1), pp.S457-S458
09/2023
DOI: 10.1016/S2152-2650(23)01369-1
Abstract
Context
EFS24 is an established endpoint in diffuse large B-cell and follicular lymphoma. Its role is undefined in MCL.
Objective
To evaluate conditional survival and cause of death (COD) after achieving EFS24 in patients with MCL.
Design
Multicohort study using Mayo/Iowa MER cohort, BC Cancer cohort, and Swedish Lymphoma Register. Two treatment eras were defined for each cohort based on local treatment pattern changes.
Main Outcome Measures
Overall survival (OS) compared with age- and sex-matched general population and COD.
Results
In the MER cohort, patients treated in Era M1 (2002-2009; n=110) and M2 (2010-2015; n=127) both had inferior OS compared with the general US population. A lower standardized mortality rate (SMR) (2.43 vs 3.95) in Era M2 suggested a narrower gap in OS vs the general population. Lymphoma was the leading COD in both eras. In Era M1, patients achieving EFS24 still had inferior OS compared with the general population (SMR=2.81); lymphoma remained the leading COD. However, in Era M2, patients achieving EFS24 had similar OS compared with the general population (SMR=1.35); lymphoma was no longer the leading COD. In the BC cohort, patients treated in Era B2 (6/2013-2019; n=188) vs Era B1 (2003-5/2013; n= 250) had a narrower gap in OS compared with the British Columbia population (SMR 4.53 vs 6.69). Lymphoma was the leading COD in both eras. For patients achieving EFS24, the gap in OS was narrower in Era B2 vs B1 (SMR 3.56 vs 4.99). After achieving EFS24, lymphoma was the leading COD for patients in Era B1 but not in Era B2. Similar results were seen in the Swedish cohort. The gap in OS compared with the general Swedish population was narrower in Era S2 (2013-2018; n=439) vs S1 (2006-2012; n=442), both after frontline chemotherapy (SMR 4.8 vs 5.4) and after achieving EFS24 (SMR 2.6 vs 3.4). After achieving EFS24, lymphoma was the leading COD for patients in Era S1 but not in Era S2.
Conclusions
In the more recent era, OS after achieving EFS24 improved and moved closer to expected background survival, and lymphoma-related mortality was no longer the leading COD.
Details
- Title: Subtitle
- MCL-063 Multicohort Study of Conditional Survival and Cause of Death After Achieving Event-Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL)
- Creators
- Yucai WangMelissa LarsonSara EkbergKarin SmedbyEric ZhaoAlina GerrieUmar FarooqMatthew MaurerJonas PaludoGrzegorz NowakowskiThomas HabermannAlexandra Albertsson-LindbladIngrid GlimeliusBrian LinkDiego VillaMats JerkemanJames Cerhan
- Resource Type
- Abstract
- Publication Details
- Clinical lymphoma, myeloma and leukemia, Vol.23(Suppl. 1), pp.S457-S458
- Publisher
- Elsevier Inc
- DOI
- 10.1016/S2152-2650(23)01369-1
- ISSN
- 2152-2650
- eISSN
- 2152-2669
- Language
- English
- Date published
- 09/2023
- Academic Unit
- Epidemiology; Internal Medicine; Hematology, Oncology, and Blood & Marrow Transplantation
- Record Identifier
- 9984461349602771
Metrics
1 Record Views